Vimseltinib for P-glycoprotein Inhibition Study

This trial tests a new treatment called vimseltinib to observe its effects on the body's handling of another drug, dabigatran. The researchers aim to understand how vimseltinib interacts with P-glycoprotein, a protein that transports drugs across cells, in healthy males. Participants will receive both vimseltinib and dabigatran over a short period to study these effects. Healthy men who feel fit and have a body mass index (BMI) between 18 and 32 may qualify for the trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that vimseltinib has been studied for other uses, providing some information about its safety. In one study, vimseltinib caused side effects in about 20% of patients, including elevated levels of the liver enzyme AST, swelling around the eyes, tiredness, and skin rashes. Another study found that vimseltinib was generally well-tolerated, with most participants not experiencing serious side effects.

Vimseltinib is unique because it targets P-glycoprotein, a protein that can pump drugs out of cells, making them less effective. Many existing treatments for conditions involving drug resistance focus on different pathways or mechanisms. Researchers are excited about vimseltinib because it has the potential to improve the effectiveness of other medications by inhibiting this protein, potentially leading to better outcomes for patients who struggle with drug resistance. This represents a novel approach compared to standard treatments, which often do not address the role of P-glycoprotein in reducing drug efficacy.

Research has shown that vimseltinib can be quite effective for certain conditions. In studies on tenosynovial giant cell tumor (TGCT), 40% of patients experienced significant tumor shrinkage, and 67% saw their tumors reduce by at least 30%. The overall response rate ranged from 33% to 50%, with many patients also reporting less pain. Vimseltinib blocks signals that tumors use to grow. Although it's already approved for TGCT, this trial investigates how vimseltinib works in combination with other medications, such as dabigatran. Participants in this trial will receive a single dose of dabigatran on Day 1, followed by coadministration of dabigatran with vimseltinib on Day 5.⁶⁷⁸⁹¹⁰